HRP20160183T1 - Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava - Google Patents

Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava Download PDF

Info

Publication number
HRP20160183T1
HRP20160183T1 HRP20160183T HRP20160183T HRP20160183T1 HR P20160183 T1 HRP20160183 T1 HR P20160183T1 HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T1 HRP20160183 T1 HR P20160183T1
Authority
HR
Croatia
Prior art keywords
independently
ring
bone
compound according
image
Prior art date
Application number
HRP20160183T
Other languages
English (en)
Croatian (hr)
Inventor
Iain Robert Greig
't Hof Robert Jurgen Van
Stuart Hamilton Ralston
Original Assignee
The Univ Court Of The Univ Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Court Of The Univ Of Aberdeen filed Critical The Univ Court Of The Univ Of Aberdeen
Publication of HRP20160183T1 publication Critical patent/HRP20160183T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20160183T 2007-03-21 2008-03-20 Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava HRP20160183T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0705400.0A GB0705400D0 (en) 2007-03-21 2007-03-21 Therapeutic compounds andm their use
EP08718826.4A EP2137141B1 (en) 2007-03-21 2008-03-20 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
PCT/GB2008/000989 WO2008114022A1 (en) 2007-03-21 2008-03-20 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
HRP20160183T1 true HRP20160183T1 (hr) 2016-03-25

Family

ID=38024559

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160183T HRP20160183T1 (hr) 2007-03-21 2008-03-20 Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava

Country Status (11)

Country Link
US (1) US8524778B2 (enExample)
EP (1) EP2137141B1 (enExample)
JP (1) JP5450105B2 (enExample)
CA (1) CA2681320C (enExample)
DK (1) DK2137141T3 (enExample)
ES (1) ES2561163T3 (enExample)
GB (1) GB0705400D0 (enExample)
HR (1) HRP20160183T1 (enExample)
HU (1) HUE028656T2 (enExample)
SI (1) SI2137141T1 (enExample)
WO (1) WO2008114022A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
EP2616450B1 (en) 2010-09-17 2018-05-02 Kancera AB Sulfonamide compounds
US9422224B2 (en) 2011-06-13 2016-08-23 Ergon Pharmaceuticals Llc Methods of treatment using a BCAT1 inhibitor
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013093095A1 (en) * 2011-12-22 2013-06-27 Kancera Ab Bisarylsulfonamides useful in the treatment of inflammation and cancer
MX2015006844A (es) * 2012-12-10 2015-09-16 Hoffmann La Roche Derivados de bencilsulfonamida como moduladores del receptor huerfano relacionado al receptor de retinoide (rorc).
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
WO2015042297A1 (en) 2013-09-20 2015-03-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate can cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ES2899852T3 (es) 2014-12-17 2022-03-15 Pimco 2664 Ltd Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
PL3580571T3 (pl) 2017-02-07 2023-07-31 Lyfstone B.V. Biomarkery do diagnozowania ryzyka rewizji implantu dotyczącego implantu z powodu obluzowania aseptycznego
WO2020097408A1 (en) * 2018-11-09 2020-05-14 Nimbus Artemis, Inc. Acly inhibitors and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) * 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
GB2001307A (en) * 1977-07-01 1979-01-31 American Cyanamid Co Sulphonamide blood complement inhibitors
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
WO1997016433A1 (en) 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JP2001527513A (ja) 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
CN1238688A (zh) 1996-07-22 1999-12-15 孟山都公司 硫羟磺酰胺金属蛋白酶抑制剂
DK0938471T3 (da) 1996-10-16 2002-01-28 American Cyanamid Co Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
AU734302B2 (en) 1997-05-08 2001-06-07 Smithkline Beecham Corporation Protease inhibitors
DE59802394D1 (de) 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
CN1177832C (zh) 1998-01-23 2004-12-01 艾文蒂斯药品德国股份有限公司 作为骨重吸收抑制剂和作为细胞粘附抑制剂的新的磺酰胺衍生物
TR200002224T2 (tr) 1998-02-04 2000-12-21 Novartis Ag Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri.
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
PL357277A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
EP1399137A4 (en) * 2001-05-07 2005-12-14 Smithkline Beecham Corp SULPHONAMIDES
WO2003016254A1 (en) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
GB0126157D0 (en) 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
WO2003080042A1 (en) 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
DK1537116T3 (da) 2002-09-04 2010-09-27 Schering Corp Pyrazolopyrimidiner egnede til behandling af cancersygdomme
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
DK1638544T3 (da) * 2003-05-07 2008-03-31 Univ Aberdeen Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande
JPWO2004106290A1 (ja) 2003-05-14 2006-07-20 キッセイ薬品工業株式会社 アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
GB0324792D0 (en) * 2003-10-23 2003-11-26 Sterix Ltd Compound
OA13344A (en) 2003-12-19 2007-04-13 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity.
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
GB0405193D0 (en) 2004-03-08 2004-04-21 Medical Res Council Compounds
WO2005105712A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7470722B2 (en) * 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
ATE449094T1 (de) 2005-06-16 2009-12-15 Pfizer N-(pyridin-2-yl)sulfonamidderivate
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) * 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7560597B2 (en) * 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use

Also Published As

Publication number Publication date
GB0705400D0 (en) 2007-05-02
JP5450105B2 (ja) 2014-03-26
SI2137141T1 (sl) 2016-03-31
EP2137141A1 (en) 2009-12-30
US8524778B2 (en) 2013-09-03
HUE028656T2 (en) 2016-12-28
EP2137141B1 (en) 2015-12-02
JP2010522152A (ja) 2010-07-01
ES2561163T3 (es) 2016-02-24
US20100286266A1 (en) 2010-11-11
DK2137141T3 (en) 2016-02-29
CA2681320A1 (en) 2008-09-25
WO2008114022A1 (en) 2008-09-25
CA2681320C (en) 2015-05-19

Similar Documents

Publication Publication Date Title
HRP20160183T1 (hr) Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava
ES3004565T3 (en) Pyrrolo - dipyridine compounds for the treatment of bone loss
JP6721499B2 (ja) 骨の成長を促進するためのアルキルアミンハルミン誘導体
JP2010522152A5 (enExample)
DE60317630T2 (de) Indol, azaindol und verwandte heterocyclische pyrrolidin-derivate
AU736026B2 (en) Integrin receptor antagonists
SI2459176T1 (en) Crystallization process and bioavailability
JP2007501281A5 (enExample)
RU2005122901A (ru) Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr
CN101941990A (zh) 哌嗪和取代的哌啶抗病毒药物的前药
EA002822B1 (ru) Антагонисты рецептора интегрина
ATE286501T1 (de) Pyrimidinderivate
WO2004065365A1 (ja) ８−アザプロスタグランジン誘導体およびその医薬用途
JP2025090543A (ja) フルオロβ－カルボリン化合物
WO2018202039A1 (zh) 杂环化合物及其制备方法
ES2263033T3 (es) Derivados de pirodoindolona sustituidos en posicion 3 con un grupo heterociclico, su preparacion y su aplicacion en terapeutica.
ITMI970730A1 (it) Coniugati di bis-fosfanati con funzionalita' alchilanti aventi attivita' antitumorale
TWI492920B (zh) 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
KR20170091610A (ko) 신규 peg 유도체
RU2019111768A (ru) Противораковые агенты и их получение
CN1953985B (zh) 哌嗪和取代的哌啶抗病毒药物的前药
RU2024116795A (ru) Конъюгат антитела к trop2 человека с камптотециновым лекарственным средством и его медицинское применение
JPH11279157A (ja) バルビツール酸誘導体およびそれらからなる骨・軟骨疾患予防・治療薬
JP2013541515A (ja) 表面機能化のためのアダマンチル基本構造を有する三脚型ビスホスホネート誘導体の合成
RU2019112913A (ru) Режим дозирования соединения pth контролируемого высвобождения